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Dramatic changes in the stem cell ethical and research ecosystem in the last 10 years depended on active
engagement among scientists, ethicists, government, and public. Tracing that story demonstrates the value
of such engagement, and forecasts a successful method for meeting future challenges.Finally, it’s 2011, and stem cell research is
facing a somewhat friendly world. In the
U.S., with the stroke of an appellate
court’s pen, federal funds for embryonic
stem cell research can now flow as the
new President and past Congresses in-
tended—at least until the next judicial
bump in the road. As this year’s annual
ISSCR meeting will show, research is
pursued in almost countless directions,
connecting the dots scientifically from
pluripotency to differentiation. Within and
across specialties and countries, new
knowledge concentrates and diffuses; in
some areas, there is the palpable tension
preceding another breakthrough.
But think back on the environment only
10 years ago. A global patchwork of irrec-
oncilable political divides. High-risk legal
pitfalls for the unwary. Unbridgeable
ethical positions, not just around deriva-
tion, but around research uses and appro-
priate scientific methods. Would stem cell
research be The Abortion Debate, Part II?
Add in stifling intellectual property restric-
tions, which limited commercial research
sponsorship at the same time government
funding was scarce. In the U.S., a well-
intentioned attempt by President Bush to
craft a funding compromise, around few
cell lines, satisfied few. Groundless hype
floated beside prophetic science, and
there was no clear way for the public to
tell the difference, or know what inter-
esting experiment would pop up next on
the front page of a national newspaper:
successful human cloning? Dolly the
sheep replaced by a scientifically caged
Dolly the human, a clone exploited to
supply organs to a failing body? HumanDNA in bovine eggs? ‘‘Chimeric mino-
taurs feared,’’ said the Australian press.
Surely these were events described by
Nostradamus or Bosch, or in prophecies
of the Apocalypse. Would stem cell scien-
tists, eyes aglimmer, remember or forget
what we all have learned time and again:
that new science and new technology
always, eventually, take on a life of their
own, in ways we do not predict?
Yet here we are—no minotaurs in
evidence; no stem cell civil war. To the
contrary, wehave an extraordinary degree
of pluralistic consensus, and an inter-
twined scientific and ethical path forward
that was unthinkable in 2001. Has it really
been just 10 years? What did it take?
And what will it take, for the challenges
that remain?
We have all heard the arguments for
scientists to engage responsibly with the
public over the aims, norms, and social
consequences of their work. I have
made such arguments myself; as I wrote
in 2007, ‘‘Abandoning real public engage-
ment is not ending it. It is abandoning it to
the forces scientists fear.’’ (Taylor, 2007).
And we have all heard the arguments
why scientists can ignore social implica-
tions: ‘‘knowledge’’ is science’s business,
and science is unconstructed and value
free: leave consequences to others. We
will not replay those tapes here. Instead,
this is an opportune time to make
a different argument, an argument from
looking back, concerning the bridge that
scientists and society must construct
together, when biological novelty chal-
lenges the public and personal senses of
self and society. On what did this socialNeuronand scientific transformation rest? Is it
complete? What remains to be done?
It rested on this: devotion to actively
engaging with public discussion and
personal responsibility, over hard issues,
leading to the ISSCR’s unusual step to
donate its expertise to patients seeking
help, by turning the light of its own inquiry
on commercial purveyors of unproven
therapies (Taylor et al., 2010). This sort
of engagement is not abstract. It pro-
ceeded from real awareness that one
false step could end a career and a field.
It went beyond downloading ‘‘facts’’ and
theories to a public often portrayed as
scientifically Luddite; this was no simple
picture of the Light of Reason dispelling
the Darkness of Ignorance. There was
more serious listening, within a shared
public-scientific sphere, and joint
tinkering with how concerns were framed
and solutions proposed. More caring
about those whose lives could be
affected—from embryonic ones to adult
ones—sufficient to cut across partisan
politics. More insight that the autonomy
of science depends on themoral authority
of its actors, and that that moral authority
is earned through interaction, not through
disengagement or pronouncements that
reduce normative positions to empirical
ones. More mutual recognition of plural-
istic values inevitably in tension, a tension
to be lived with and acted through, not
ended through some ideological or prag-
matic victory. More mutual querying of
the aims and limits of science; and more
joint acknowledgment of uncertainties
and where self-regulation might focus,
than denials and false certainties. More70, May 26, 2011 ª2011 Elsevier Inc. 577
Table 1. Ethical Complexity
Diverse methods of analyzing ethics of derivation, and ‘‘moral claims’’ of blastocyst or embryo:
absolute right of embryo not to be destroyed at conception versus:
staged correlation between rights and physical qualities (capacity)
rights dependent on potential capacity: rights if potential capacity in theory versus rights depend on real capacity, i.e., rights only if embryo is in
an environment sufficient to develop to its capacity, through implantation
absolute right, versus right potentially outweighed by other social goods (discounted by potential alternatives, e.g., adult stem cells)
rights of the biological parents:
scope includes destruction (IVF), donation (IVF), special creation, and destruction for research purpose?
how rights are exercised: mandatory separation of destruction and donation decisions?
donation provenance: donors how informed, and of what?
relevance of facts to ethics: Determinative (e.g., Warnock Commission 14-day rule)? Informative but not determinative (e.g., fetal mouse brain
replacement by human embryonic stem cells informs but does not determine ethics of whole-brain chimeric replacement)?
IVF embryos
defining ‘‘excess’’ embryos
defining abandonment
informed consent
destruction and research disposition?
both gamete providers?
use limits
how informed is informed?
Somatic Cell Nuclear Transfer
tissue cultivation versus new life
informed consent of somatic cell donors and egg donors
compensation and other issues regarding donors
when does it end?: reproductive cloning and fetal organ harvesting
New ‘‘technologies’’
research uses of nonprogressing embryos (created for reproductive purposes, fail to thrive and develop)
reprogramming of adult cells (iPSCs): unknown risks and potential
fission of PGD embryos
chimeras:
general prohibitions versus special limitations (germline, neuro tissue)
limited to gestation, or raise through adulthood?
breed, permit second-generation offspring?
Other ethical issues
truth-telling with investors, press, consumers, and government
fair distribution of benefits on affordable terms
data sharing and research progress
resource allocation (biotechnology versus preventive care)
‘‘commoditization:’’ markets and patents
the quest for immortality: moral failure to accept death as part of life?
effects on ‘‘personhood’’ of neural transplant recipients
Clinical trial-related ethical issues
phase I testing in health volunteers (lessons from gene therapy?)
nature and quality of preclinical evidence
justice in disease selection and recruitment
avoiding the therapeutic misconception (where public expectations are so high)
avoiding ‘‘coercion’’ where needs are so dire
how to address incremental medical innovation?
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Table 2. Intellectual Property
Restrictive IP environment
one owner of patents on composition and methods of one technology, human embryonic
stem cells
restrictive corporate and academic licensing: attempt to eliminate all commercially sponsored
academic research unless sponsor had costly, up-front WiCell license
Academic research licenses are available, and do not prohibit licensing inventions, but:
prohibit providing any benefits or ‘‘rights’’ to commercial sponsors, collaborators, or material
providers
prohibit any transfer of materials to unlicensed commercial entities
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joint commitment to future research. The
point is this: through such means is the
social context for cutting-edge science
built. Nothing less.
Ten Years Ago
Although there are many planes along
which we might observe, let’s take three
accessible ones, summarized in Table 1,
Table 2, and Table 3. Discussion among
ethicists, and to some extent the public,
focused on the ethics of derivation. Yet
other ethical issues emerged early and
were not forgotten. Positions clustered
around distinct avenues: the absolute,
noncontingent prohibition on embryo
destruction for stem cell research, to
staged equations of embryonic rights
against actual capacity or developmental
potential, theoretical or real. All but the
first position could envision some circum-
stances under which embryonic stem cell
derivation would be ethical, provided that
the intentions and actual benefits of doing
so were aligned around healing, particu-
larly in connection with pathologies not
presently treatable. At the other extreme,Table 3. U.S. Federal Funding
U.S.: Dickey-Wicker (no NIH funds for research in
administrative duplication of facilities; fear produc
with trend toward treating research billing mistake
treble damages, civil sanctions)
Financial support only for ‘‘Presidential Lines’’ (pe
does not harm embryo)
Funding-dependent research ethics standards (da
on Presidential Lines
Segregated duplicate equipment and systems for
Tracking obligations
Open questions:
federally funded research on non-Presidential der
products of Presidential Lines in non-federally fun
Severe risks: criminal and civil penaltiesall could also envision some circum-
stances, and some forms of embryonic
stem cell research, that would be wrong
or even morally catastrophic.
With ethics depending on conditions
and consequences, in fact, identifying
ethical conditions, and assuring their
occurrence, waswidely seen as an essen-
tial task. What are the legitimate powers
of donors? Can one create embryos for
the purpose of research, or may research
be conducted only on those already fated
for destruction through independent
choice? How long is too long to maintain
an embryo in vitro? Do research methods
matter? In what ethical environment must
research occur? How should these ques-
tions be answered—within the disciplines
of bioethics or developmental biology, or
across disciplines and with public input?
Would answers come from extrapolating
from past intuitions or from listening to
current and public ones as well?
Ensuring that the benefit would be real
meant that intellectual property became
compellingly relevant to practical ethics.
Forget pretending, on one side, that the
public will benefit, while, on the other,volving death of embryo); consequences:
ed by unclear legal boundaries, combined
s the same as health care fraud (OIG,
rhaps evolving under vague standard:
ta and materials sharing): limited to research
research with non-Presidential Lines
ivatives?
ded research?
Neuroninsulating intellectual property decisions
from popular sentiment or practical effect
behind the walls of government patent
offices and university tech transfer
seeking profit over benefit. The ideals of
the scientific community and the disci-
pline of socially just access become
linked to the ethical legitimacy of the
research itself.
Yet, the effect of federal funding policy
was that the key regulatory foundations
for ethical scientific research did not apply
to most stem cell research, precisely
because the whole structure of data and
materials sharing, research integrity and
misconduct, and ethical review is linked
to federal funding (see Table 4). If ethical
review and property were to be regulated,
they had to be self regulated, or they
would not be regulated at all. But this
would be self regulation in the public
eye, not behind the closed doors of
a conference retreat, self-regulation
which would be critiqued in newspapers
and leading journals, and would answer,
or obviously fail to answer, the stated
concerns of diverse members of the
public, and government members of all
parties and persuasions, and globally so,
not just locally.
So while U.S. law fumbled on, coarsely
translating ethical nuance into what to
fund, and nations and states diverged,
extraordinary discussion bypassed the
ordinary organs of democratic govern-
ment. Mechanisms for the generation of
standards evolved. Some, like standards
of the U.S. National Academy of Sciences
(NAS), were precise, professional, and not
initially particularly democratic, involving
the application of proficient and consci-
entious expertise to creating standards
for the ethical conduct of stem cell
research, addressing problems perceived
and, with deep insight, some yet to be
perceived. The standards of the Interna-
tional Society for Stem Cell Research
(ISSCR) (Daley et al., 2007; Hyun et al.,
2008; Taylor et al., 2010) was a compa-
rable effort, but with four significant differ-
ences. First, the effort was deliberately
global from inception to application.
Second, it invited public comment. The
result of the latter was unmistakable:
drafts and redrafts, discussions and re-
discussions, around how problems and
solutions were perceived and articulated,
and whether justifications spoke not only70, May 26, 2011 ª2011 Elsevier Inc. 579
Table 4. Implications of Federal Funding Scarcity plus IP Restrictions
Limited number of lines available for federally funded research, grown on mouse feeder cells
Excluded genetic diversity and subsequent alternative methods (e.g., SCNT and
parthenogenesis)
Materials transfers, data sharing, and patent uses restricted
Commercially funded research financially constrained by holder of stem cell patents through
unique academic and commercial license restrictions, but not constrained by federal standards
of scientific ethics
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who would disagree; if not persuasive,
then at least arguments were taken seri-
ously. Third, it conceived ethics broadly,
addressing not just laboratory minutiae,
but social justice in research choices,
broad access to stem cell therapies, and
intellectual property and data sharing
among haves and have-nots. It translated
theory into imperatives, so the norm of
universal sharing, explicitly expressed,
was translated into specific institutional
obligations and concrete applications
like model consent documents andmodel
materials transfer agreements, which
were transparent for public feedback.
Fourth, longitudinally, it did not stop
at the lab door, but tried to trace the
trajectory from basic research through
translation to clinical research, medical
innovation, and—their snake-oil-bearing,
false cousin—the sale of unproven thera-
pies as cures to desperate patients and
their families.
The ISSCR and NAS were hardly alone
in this effort (Taylor, 2010). Leading jour-
nals not only publicized these efforts, but
critiqued them, directly and indirectly,
and countered. Some government
agencies, particularly in the U.K., experi-
mented and taught, while other govern-
ment branches inquired and challenged.
Crossing national lines, consortia like
The Hinxton Group engaged in focused
attention on transnational cooperation
and special issues like gamete produc-
tion and new ways to decrease the
barrier effect of intellectual property on
global justice and innovation (The Hinx-
ton Group, 2006, 2008, 2011). Nascent
stem cell review and oversight commit-
tees began the hard work of protocol-
specific review, feeding back what
worked and what failed among new stan-
dards. Organizations like Public Respon-
sibility in Medicine and Research
(PRIM&R) directed some of their extraor-580 Neuron 70, May 26, 2011 ª2011 Elsevierdinary organizational and educational
skills to shared policy-making, discus-
sion, and evaluation. European and North
American stem cell banks and registries,
networks, and consortia of networks, in
consultation with scientists, government,
and public, began to formalize scientific
and ethical requirements that would
govern what materials would be banked
and distributed, and played a critical
role in interacting with desperate patients
and formulating a response. Some politi-
cians made it a hallmark of their integrity
to develop nuanced positions, neither
disrespectful of their opponents nor
shallow in thinking through what they
believed.
The Effect
The effect is what we have today. In
public ethics, there is nuanced support
for a range of options, but primarily for
research on stored IVF embryos initially
created for reproduction, that will not,
through parental choice, be implanted,
and subject to the parents’ specific dona-
tion for research. Few regard this deci-
sion, or the consensus, lightly. There are
consensus standards on most ethical
issues involving the original donation,
informed consent, and provenance—
including criteria shared among public,
scientists, stem cell banks, and registries
and independent ethical review bodies.
There are ethical standards for chimera
research, revisable as the characteristics
of chimeras become known, and there is
as active search for factual characteris-
tics that would make normative differ-
ences. Guidance addresses almost every
issue in Table 1. Self-regulatory guidance,
administered through self-regulatory
committees with public membership,
remains, though, as the major source of
practical ethics.
The combination of standards, peer
pressure, leadership changes, and scien-Inc.tific developments has altered the intellec-
tual property landscape completely. The
main human embryonic stem cell patent
holder retreated from requiring academic
licenses; multiple ‘‘technologies,’’ in-
cluding nonpluripotent derivatives and
induced pluripotent cells, reduced the
impact of the human embryonic stem
cell patent position; and other patent
holders tacitly follow a different course of
tolerating academic unlicensed use.
Recognition of health risks has led to in-
tertwining ethical concerns with lines of
further research. Thus, researchers have
directed their attention to genes and
factors affecting cancer risks and uncon-
trolled development and the development
of pluripotent alternatives with select
oncogene deletions for induced pluripo-
tent cells, have adopted as a foundation
the tissue regulatory framework useful
elsewhere, and, most importantly, have
reached scientific and ethical agreement
on a strict, transparent, data-based, and
controlled translational and clinical
research pathway, without shortcuts, as
the basis for any human applications of
human embryonic stem cells or direct
derivatives.
The latter became the technical founda-
tion for the ISSCR’s outreach to commer-
cial purveyors of stemcell therapy. But the
moral and political foundation was neces-
sarily broader, requiring ‘‘the essential
relationship that exists between scientific
progress and public responsibility,’’ and
‘‘the long-standing commitment of the
ISSCR to ethical and scientific self-regula-
tion through globally representative
consensus on standards that distinguish
sound and ethical stem cell science from
practices that would be unethical or
unsound.’’ (Taylor et al., 2010.)
Many challenges remain, both for this
research and for policy-making (Zar-
zeczny et al., 2009). Some are old at
root but new in dimensions, such as pro-
tecting desperate patients from facile
consent to unworthy experiments. Some
are larger, such as giving meaning to
justice, and keeping foundational ethical
commitments to ensuring that both
benefits and risks are actually fairly
distributed across society. Some are
larger still, and entail perfecting and em-
ploying, consistently, what Jasanoff
(2003) has baptized ‘‘technologies of
humility,’’ specified social technologies
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NeuroViewfor democratic interengagement—or is it
intraengagement?—with science.
As a participant in the history above, I
no doubt have brought to the analysis
my own misperceptions and biases, but
I have no apologies, for its essential
lesson is true and clear, and marks the
difference between where we were and
where we may yet fully arrive, through
active and deep commitments to public
engagement.
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